



Our Mission: To advocate for those affected by lupus and allied diseases through awareness and research program initiatives to improve quality of life.

Lupus Communiqué

Lupus and Allied Diseases Association, Inc.

Volume 11, Annual Edition 2014-2015

ANNUAL RESEARCH DONATION



Lupus Research Institute Chairmen Jack Lavery (left) and Robert Ravitz (right) and Annie Ravitz (center right) receive our Annual Research Donation of \$20,500 which represents a little over 1/3 of our annual income for 2014 from Lupus and Allied Diseases Association President & CEO Kathleen Arntsen (center left) on October 20, 2014 at the LRI Annual Scientific Meeting. We are extremely proud that we have invested \$270,000 over the past 13 years for novel, innovative and successful lupus research at the LRI.

Lupus and Allied Diseases Association, Inc. is a tax-exempt charitable organization eligible to receive tax-deductible contributions under IRS Code Section 501(c)(3). Our federal tax identification number is 16-1083229 and a copy of our latest annual report may be obtained upon request from us or The NYS Attorney General's Charities Bureau at 120 Broadway, NY, NY 10271.

Since we are no longer collecting membership dues, please consider Memorial and Tribute contributions to our organization. It is a wonderful way to honor or remember someone special in your life while also supporting the lupus cause. If you belong to a Service or Fraternal organization, or participate in a workplace-giving program such as: SEFA, UNITED WAY, IBM or other campaign, please remember to designate our organization..

EDITOR'S NOTE

Suggestions or comments on the newsletter are always welcome. Please contact us with any address changes or other corrections to ensure accuracy in the database. If an address is incorrect the Post Office will not deliver under their revised policies and the mail piece will be returned and we will be charged a fee. Please notify us immediately of any changes to avoid extra postal fees. As Technical Director I also invite your input and assistance in improving our organization's operations, especially in maintaining our website. Thank you.

Dave Arntsen

Lupus and Allied Diseases Association, Inc. is proud to be a member of the

- ◆ **National Coalition of Autoimmune Patient Groups**
- ◆ **Lupus Research Institute National Coalition**
- ◆ **NIAMS Coalition**
- ◆ **Lupus Agencies of New York State**
- ◆ **NIAMS Lupus Federal Working Group**
- ◆ **Coalition for Accessible Treatments—CAT**
- ◆ **New York BIO**
- ◆ **BIO NJ**
- ◆ **New York State Rheumatology Society—NYSRS**
- ◆ **Patients for Biologics Safety & Access—PBSA**
- ◆ **New Yorkers for Accessible Health Coverage—NYFAHC**
- ◆ **Health Care for all NY—HCFANY**
- ◆ **Coalition for Clinical Trials Awareness—CCTA**
- ◆ **Alliance for Access to Innovative Therapies—AAIT**



Beanie Bears \$10 each

The Lupus Communiqué

*Is published once a year by
Lupus and Allied Diseases Association, Inc.
PO Box 170 Verona, NY 13478*

Phone: 315-829-4272 or 1-866-258-7874

Fax: 315-829-4272

E-mail: LupusInnovators@aol.com

www.NoLupus.org

Editor: David L. Arntsen

TABLE OF CONTENTS

Research Donation	1
Newsletter Information	2
Campaigns	3
President's Message	4-5
LRI Article	6
Biosimilar Article	7
Golf Classic Photos	8-9
Golf Classic Poster	10
Golf Classic Form	11
May WLD Victorian Tea	12
Memorials, Tributes & Donations	13-15
Awareness & Advocacy Photos	16

DISCLAIMER

It is the policy of the Lupus and Allied Diseases Association, Inc. to publish articles on Lupus and related diseases that have been written by physicians, nurses, and other healthcare providers and medical professionals. The opinions and statements expressed by the authors or contributors to this publication do not necessarily reflect the opinions or positions of The Lupus Communiqué, or Lupus and Allied Diseases Association, Inc.

The material published herein is provided for informational purposes only and does not imply endorsement of any specific treatment, product, clinical trial, company or organization. We oppose self-diagnosis and self-treatment and urge readers to discuss any concerns they may have regarding diagnosis and treatment with their physicians. All rights reserved. No material in this issue may be copied or published without the express written consent of Lupus and Allied Diseases Association, Inc. Thank you.

BOARD OF DIRECTORS

President/CEO
Kathleen A. Arntsen

1st Vice President
Sandra M. Frear

2nd Vice President
Jacqueline L. Taylor

Treasurer
Philip A. Teague

Secretary
David L. Arntsen

Members

Dale R. Bullock

Richard D. Deyulio

Ellen C. Gloo

*Honorary
Medical Advisory Board*

Atul Butala, MD
Hematologist

Gregory Cummings, MD
Neurologist

Victoria Laucello, MSW
Psychotherapist

Edward B. Lee, MD
Dermatologist

Martin Morell, MD
Rheumatologist

Khalid Parvaiz, MD
Nephrologist

Donald Raddatz, MD
Rheumatologist

Raquel Rosen, MD
Nephrologist

Allan Smiley, MD
Rheumatologist

President's Message—

I realize that I usually begin my message with a poetic comment about the weather but as it is still snowing and frigid in late April in Central New York, I am at a loss for any prose that would be appropriate other than Seriously! Since it has been over a year since our last annual newsletter I would like to share our organization overview and accomplishments with you. As we previously told you the Board voted to transition the organization to build on our advocacy and research strengths.

We are proud to say that although it took longer than expected, Lupus and Allied Diseases Association name, address, mission, purposes and bylaws have all officially been approved. We are a passion driven, patient-focused, all-volunteer charitable organization dedicated to improving quality of life for those impacted by lupus and allied diseases and conditions of unmet need by fostering collaboration among stakeholders and promoting innovative and promising advocacy, awareness and biomedical research program initiatives.

Our organization believes it is critical for all health care stakeholders to collaborate on advocacy and research initiatives and that the patient voice must be included. We are very active on both the state and national level regarding health care reform and access issues that impact all Americans especially by providing stronger patient protections. Because lupus is a multi-system autoimmune disease and is unpredictable and highly individualized, having access to the full array of treatments is important to us. We are passionately committed to ensuring that all Americans receive the most appropriate therapies as directed by their treating providers and that drug development and discoveries continue to progress rapidly to improve quality of life. We are also expanding our collaborative efforts with other biopharmaceutical stakeholders to promote patient-centered care and to ensure public policy keeps pace with biomedical research innovation. We believe that medical research and development needs to be encouraged; not stifled by bureaucracies so that all individuals, regardless of race or socioeconomic status can live longer and healthier lives.

Now that we are a national organization and recognized as a strong grassroots collaborative group, we were invited to join several advocacy coalitions and provide public comments regarding important research initiatives. We have been and will continue to boldly insert ourselves into the research and development communities whenever possible to make sure a patient perspective is included. We are proud to say that organizations like BIO, NY BIO, BIO NJ, NYS Rheumatology and the American College of Rheumatology are visionaries and have welcomed patient advocates with open arms, but most organizations do not see patients as equal stakeholders. Patients like me who take nearly 40 drugs a day and deal with our complicated healthcare system daily have a wealth of information to share. “The patient perspective is powerful, passionate, persistent, persuasive and non-proprietary.”

We are thrilled that we are in an era of patient-centric and patient-engaged initiatives. For decades the patient perspective was not welcome nor appreciated and basically ignored. Advocates like me fought tenaciously for the patient voice to be present and have an equal say in health care, research and development. Bearing witness to these achievements has brought a sense of pride and fulfillment to those of us who have been a catalyst of change in pushing for these endeavors. But things move far too slow and get lost in the politics and bureaucracy while individuals struggling to manage complicated, debilitating, volatile, and potentially fatal diseases of unmet need like Lupus and those who love, advocate for, and treat them continue to wait; we are impatient.

We may be a small organization but we are mighty. We are the lead group organizing The Lupus Agencies of NYS 6th Annual Awareness Day in May in both houses and have lupus education and research bills introduced. We just collaborated with the NYS Rare Disease Alliance, NORD and NY BIO for the 2nd Annual Rare Disease Day and helped procure legislative sponsors for a NYS Resolution and the entire group was recognized in both houses. We are a member of both NY BIO and BIO NJ now; attending both the NY BIO Advocacy Day and the BIO Fly-In in DC annually. We have attended NY BIO's Annual Scientific Meeting for 5 years now and participated as panelists and were honored to be guests at the BIO NJ Annual Meeting & Dinner. We just attended the American Autoimmune Related Diseases Association's Summit and I participated as a panelist in their Congressional Briefing on Biosimilars as well as the LRI Coalition's Annual Advocacy Event and the Reintroduction of the Patients' Access to Treatments Act in Washington, DC.

Advocacy has been and will continue to be a major part of our program services. We not only advocate for people affected by lupus and other diseases of unmet need but also for health care reform and patient access to care issues which affect each and every American including: the ACA implementation, protecting Medicare and Medicaid programs, ensuring strong patient protections exist, supporting NIH and biomedical research programs, commenting on FDA guidance for Biosimilars and other relevant issues, and advancing health information technology. If you have a personal story about a health care access issue that has impacted you or someone else then please share it with us.

We address access to care issues as they arise, often taking the lead to organize grassroots efforts within the state or nation. We are a lead group on advocacy efforts in NYS and have helped to coalesce 60 patient and professional groups to unite on these important efforts. We have also supported access issues in various states and have led and collaborated on national efforts. We sent comments on the 21st Century Cures and Senate Healthier Americans Initiative and led the effort for the entire lupus community to submit comments to the FDA on Patient-Focused Drug Development. I recently returned from the CDC Public Health Agenda for Lupus as a steering committee member. It has been a busy time but we remain committed to improving access to treatments and driving research and development forward with the patient as an equal stakeholder.

Our various community education programs are designed to empower people to become more proactive in their own health care and to become engaged in the public policy process. We continue to promote our “The Power of Advocacy—Promoting Participation to Improve Care” an informative presentation on how to become an effective personal and public advocate with an overview of current access and health policy initiatives and “Hope is on the Horizon” program to educate consumers on the importance of clinical research trials in getting new treatments to patients.

Our organization strongly supports innovative research initiatives that include cross-sector collaborations, public-private partnerships and robust basic, clinical and translational projects that enable scientists to: investigate disease pathogenesis and physiology, design better clinical trial methodologies, improve diagnostic tests, identify biomarkers, develop safer, more effective treatments, prevent complications, and ultimately, discover cures. We invite you to partner with us to accelerate biomedical research and development to ensure the next generation of lupus and autoimmune patients has a better quality of life and the opportunity to pursue their dreams.

On a sad note, Annie Ravitz passed away in January after courageously battling lupus for decades. The lovely daughter of Francine and Robert Ravitz, co-chairman of the LRI, Annie was an inspiration to all who knew her. David and I had the extreme honor of attending her celebration of life, surrounded by her beautiful family and loved ones. May her legacy live on through the tremendous research advances at the Lupus Research Institute.

We would like to recognize our Board Members who retired this past year: 1st Vice President and former Secretary Stephanie Darwak, and Directors Jaime Venditti and Julie Miner. We thank them for their support, dedication and volunteerism. Their input was vital in helping our organization grow into the advocacy powerhouse it is today. We wish them the best of luck in their endeavors. Thank you Ladies!

2014 was another record breaking year for the annual Golf Classic proceeds raising over \$74,000 with a net of \$57,000. We are very proud of the fact that we donate one-third of our revenue each year to lupus and autoimmune research. In the past 13 years we have donated \$270,000 to the Lupus Research Institute for novel research. We at The Lupus and Allied Diseases Association, Inc. are proud to play an active role and honored to represent you during these thrilling times. We are extremely thankful for your ongoing support; afterall, Lupus ends with US!

Hope for Warmer Weather and Be Well—Kathleen

LRI: Celebrating the 15 Years that Changed the Face of Lupus Research

“Every great advance in science has issued from a new audacity of the imagination.”

John Dewey, philosopher

That guiding principle is what brings the Lupus Research Institute (LRI) to our 15th anniversary – a milestone in our history and in our future. To encourage scientists to take risks; to take away constraints to creativity; to fund the most novel and audacious research to understand, treat, prevent and cure lupus – that is what the Lupus Research Institute set out to do. And with all of your help – our scientists, our advisors, our donors, our patients and their dedicated families – we have turned lupus research upside down.

- \$200 million delivered for innovative, groundbreaking research. With an investment of \$50 million in original ideas, LRI leveraged over \$150 million in additional funding from the NIH and others to continue the novel research initiated with our grants.
- New talent and ideas to lead the field. LRI funded over 150 investigators from diverse disciplines, many working in lupus for the first time. Their new perspectives and expertise expanded the scope and ambition of lupus research.
- Deep understanding of human lupus. LRI pushed forward the scientific agenda by championing investigations in human lupus. Over half of LRI research focuses on cells and tissues from patients, generating deep knowledge of the human disease that directly informs the development of new medicines.
- Breakthrough discoveries to propel new treatments. LRI-funded discoveries on the immune system in lupus and how it damages vital organs such as the heart, kidney and brain have spurred the development of new treatments like belimumab. LRI advances in understanding lupus propel innovative targeted therapies now being tested in patients and even more following in the pipeline.
- Driving to prevention and cure. LRI’s \$1 million Distinguished Innovator Awards, launched in 2012, challenge the global scientific community to uncover the root causes of lupus that drive to prevention and a cure.

Read more about how LRI’s cornerstone strategy of funding innovative scientific ideas in lupus has more than demonstrated its power to make significant breakthroughs in understanding a complex disease. We now have the knowledge and tools to innovate across the full spectrum of lupus research – fundamental, human, translational and clinical research – to propel the delivery of new treatments and diagnostics to patients. At the LRI we will continue to turn lupus research upside down and push for the ultimate goals of prevention and cure. And at the same time, drive creative, new practical solutions so patients can be identified earlier, and treated with safer and more effective medicines to protect them from life-threatening organ damage.

Thank you for your support as we work to transform the lives of those with lupus today and to prevent and cure lupus tomorrow.

Investment in novel research

\$50 Million invested by LRI in novel research.

168 grants awarded to date—161 Novel Research Grants and 7 Distinguished Innovator Awards.

Leverage

Generated over \$200 Million for lupus research. LRI’s investment of \$50 Million multiplied four-fold. LRI investigators have been awarded \$151 Million in extended funding, primarily from the National Institutes of Health.

Discoveries with impact

84% of investigators confirmed novel hypotheses, winning substantial follow-on funding or publishing in thought-leading scientific journals.

Over 350 published research papers credit LRI funding.

(LRI Article-continued)

Expanding the field

Over one-third of investigators come from other disciplines to work in lupus for the first time; 80% of those newcomers remain in the field long term.

LRI funded investigators at 75 institutions across 25 states, United Kingdom and Australia – an integrated, international network of investigators from diverse disciplines, all dedicated to novel research in lupus.

Sustained success

88% of projects remain active after the completion of the grant and continue to influence the field; even a decade after the original LRI investment, the majority of projects continue to deliver new insights and propel new therapies.

Human lupus biology

50% of LRI grants involve investigation of human tissue, blood or genetic material. These novel studies of human lupus biology provide new understanding directly relevant to the human disease that can be translated rapidly to new clinical applications.

- Source Lupus Research Institute *February 26, 2015*

See more at: <http://lupusresearchinstitute.org/lupus-news/2015/02/26/2015-lri-%E2%80%93-impact-research-innovation#sthash.4ZT9JAXf.dpuf>

First Biosimilar Approved

Lupus and Allied Diseases Association President & CEO and National Patient Advocate Kathleen Arntsen gave public comments from a patient perspective regarding the difficulties of treating complex autoimmune disease patients on January 7th at the FDA Advisory Committee meeting reviewing the application for the first proposed biosimilar to NEUPOGEN, a biologic treatment for neutropenia.

Biologics are complex large molecule medicines manufactured from living organisms. Biosimilars are follow-on biologics and unlike generic copies of traditional small molecule drugs, biosimilars will be therapies that are similar to, but not the same as, the original product.

Among 18 public speakers, Kathleen expressed a prevailing viewpoint among patient stakeholders urging the FDA to require additional clinical trials, especially in subpopulations and post-marketing surveillance to be conducted to ensure safety, efficacy and tolerability. At the end of the meeting the Advisory Committee recommended that the FDA approve EP2006, as a lower-cost biosimilar to Neupogen, a biologic drug used to help cancer and autoimmune patients fight off infection while taking immunosuppressive drugs because of neutropenia.

On March 6, 2015 the U.S. Food and Drug Administration approved the first biosimilar drug Zarxio – a close copy of the existing biologic medication Neupogen. The approval of Zarxio has implications for lupus because it poses the possibility of FDA approving other biosimilars for biologic drugs used to treat lupus.

Our organization remains very vigilant in following the pathway to develop and regulate biosimilars and considers it a priority issue for all impacted by diseases of unmet need like lupus.

14TH ANNUAL LUPUS CHARITY GOLF CLASSIC



GOLF CLASSIC WINNERS



What a day to break a record! The 14th Annual Lupus Charity Golf Classic was held on August 21st, 2014 -- an intermittently rainy day at Shenendoah Golf Club at Turning Stone Resort in Verona, NY. More than \$57,000 net and a new fundraising record was set to support our program services.

Closest to the Pin



Longest Drive



15th Annual

LUPUS
Charity Golf Classic



**Shenandoah Golf Course
at
Turning Stone Resort**

Thursday, August 20, 2015

Proceeds Benefit:

**Lupus and Allied Diseases
Association, Inc.**

A Premier Charity Golf Tournament

Registration - 11:30 AM

Shotgun Start - 1:00 PM

Tournament Format: Captain & Crew 4-Person Scramble

LUNCH - GOLF - AWARDS BANQUET - PRIZES

Accepting Registration for:

Teams - Pairs - Individual Golfers

Men, Women, Senior and Co-Ed Categories

Early Registration by July 17th \$175 per golfer

Registration after July 17th \$200 per golfer

Sponsorship Opportunities Available




**Help to Make a Difference for those Affected by Lupus
While enjoying a great round of golf**

Honorary Chairman - Donald A. Raddatz, MD

Bassett Healthcare Rheumatologist

**For more information on Registration, Sponsorships or Prize Donations
Call 315-829-4272 or e-mail lupusinnovators@aol.com
or visit our website www.nolupus.org**



FIFTEENTH ANNUAL LUPUS CHARITY GOLF CLASSIC

AUGUST 20, 2015

Shenendoah Golf Course
Turning Stone Resort Casino



SPONSORSHIP FORM

Corp. Name: _____

Attention: _____

Address: _____

City/ State/ Zip: _____

Phone: _____ E-mail: _____

- \$10,000 EVENT Sponsor** – Complimentary Foursome, logo display on event & promotional materials, dinner tables, carts, banner display, tee sign, program listing, dinner recognition
- \$6,000 DIAMOND Sponsor** – Complimentary Foursome, logo display on event, dinner tables, carts, banner display, tee sign, program listing, dinner recognition
- \$4,000 DINNER Sponsor** – Complimentary Foursome, logo display on dinner tables, banner display, tee sign, program listing, dinner recognition
- \$2,500 LUNCHEON Sponsor** – Complimentary Foursome, logo display on luncheon counter, banner display, tee sign, program listing, dinner recognition
- \$1,500 CART Sponsor** – Complimentary Foursome, logo display on carts, banner display, tee sign, program listing, dinner recognition
- \$1,000 PLATINUM Sponsor** – Complimentary Foursome, banner display, tee sign, program listing, dinner recognition
- \$500 GOLD Sponsor** **\$250 SILVER Sponsor** **\$100 BRONZE Sponsor**
Tee sign, program listing
- Other Donation** – Please list _____

*All foursomes include 18 holes of golf w/cart, lunch, and dinner for four

For additional information call: 315-829-4272 or 1-866-2-LUPUS-4 or E-mail LupusInnovators@aol.com

Please make checks payable to: *Lupus and Allied Diseases Association PO Box 170 Verona, NY 13478*

An Invitation to Celebrate World Lupus Day

WHAT: Victorian Tea

WHERE: Your Home

WHEN: May 10, 2015

Recipe for a successful tea party:

1. *Dust off the stove*
2. *Find the teapot (a mug & microwave will also work)*
3. *Cookies Optional*
4. *Turn off all phones and electronic devices*
5. *Kick off your shoes*
6. *Play your favorite music*
7. *Write out your donation check*

Please consider supporting the Lupus cause this Spring by participating in our World Lupus Day Victorian Tea. Proceeds from this non-event will be used to fund our Organization's Program Services:

Newsletter Printing & Postage
Lupus Awareness, Advocacy and Public Education Programs
Continued Training to update our leaders on current information
Distribution of lupus materials for awareness events
Telephone hotline and website

Please make checks payable to:

***Lupus and Allied Diseases Association
PO Box 170
Verona, New York 13478***



Thank you for your Consideration and Support!!!

The Lupus and Allied Diseases Association, Inc. is a tax-exempt charitable organization eligible to receive tax-deductible contributions under IRS Code Section 501(c)(3). Our federal tax identification number is 16-1083229 and a copy of our latest annual report may be obtained upon request from us or The NYS Attorney General's Charities Bureau at 120 Broadway, NY, NY 10271. For more information on our event please contact us by phone at 315-829-4272 or e-mail lupusinnovators@aol.com.

Memorials, Tributes, and Donations

Memorials

In Loving Memory of...

*Bernie Carter-
Bob & Cathy Walseman
Isabel Woolshlager
Jeffrey & Susan Virkler & Family
Larry & Karen Woolshlager & Family*

*Ethel Clark-
Isabel Woolshlager*

*Wellington Walseman-
Bob & Cathy Walseman*

*Douglas Kerr-
Bob & Cathy Walseman*

*James McCarthy-
Larry & Karen Woolshlager*

*Eleanore Iglesias-
Lisabeth Iglesias*

*Louis Smith
Christine Marie Smith-
Dave & Kathleen Arntsen*

*Marguerite Curri
Peter & Dorothy Curri
Angela "Aya" Lo Conti
Michael P. Jones
Elizabeth Jones
Rosemary Franklin-
David & Kathleen Arntsen*

*The Reverend S. Kenneth Arntsen-
David & Kathleen Arntsen
Marian J. Arntsen*

*Richard W. & Penny L. Cassin-
Helen E. Cassin*

*Barbara M. Porter-
Helen E. Cassin
John Zeock
Bill & Sandi Frear*

*Joseph Jupin-
Victoria Jupin*

*Bonnie J. Martin-
Kay J. Falcone*

Memorials

In Loving Memory of...

*Lorna E. Relf
Louis A. Relf
Sam Relf
Elva Fox
Arthur A. Relf
John & Alberta Bagley
Elmer & Alice Bagley-
James & Patricia Mitchell
David & Kathleen Arntsen*

*Shawna Lynn Mitchell
James E. Mitchell
Mary Alice Mitchell
Harold Leach
Catherine Leach
James E. Mitchell
Elizabeth Mitchell
Thomas P. Mitchell-
James & Patricia Mitchell
David & Kathleen Arntsen*

*Isabell Zeock-
John Zeock*

*Harold F. Woolshlager-
Bob & Cathy Walseman
Isabel Woolshlager
Jeffrey & Susan Virkler & Family
Larry & Karen Woolshlager & Family*

*Elwood Virkler-
Jeffrey & Susan Virkler & Family*

*Anita Curtiss-
Larry & Karen Woolshlager & Family*

*Jim, Mary Alice & Tom Mitchell-
Jane Williams*

*Brooke N. Walseman-
Bob & Cathy Walseman
Isabel Woolshlager
Jeffrey & Susan Virkler & Family
Larry & Karen Woolshlager & Family
Jack & Marcia Flint & Family*

*Angelo J. "Joe" Marotta-
Frank & Lyn Soja*

Memorials, Tributes, and Donations

Memorials

In Loving Memory of...

*Brooke N. Walseman-
Bob & Cathy Walseman
Isabel Woolshlager
Jeffrey & Susan Virkler & Family
Larry & Karen Woolshlager & Family
Linda Walseman*

*Rose McCarthy-
Larry & Karen Woolshlager & Family*

*Carol Honors-
Larry & Karen Woolshlager & Family*

*The Reverend S. Kenneth Arntsen-
Marian J. Arntsen*

*Mary Alice Mitchell-
Jane Williams*

*James E. Mitchell-
Jane Williams*

*George B. Williams-
Jane Williams*

*Thomas P. Mitchell-
Jane Williams*

*Anita Russell-
David & Kathleen Arntsen
Carl T. Wrubel and
William H. Merrill
Anne Dunn
Marcia Keeney*

*Thomas & Sheila Sullivan
James & Patricia Mitchell*

*Doris Walseman-
Bob & Cathy Walseman*

*Betty C. Fitzgerald-
Bob & Cathy Walseman
Larry & Karen Woolshlager*

*Mary Ellen DeCarlo-
Peter DeCarlo & Family*

Memorials

In Loving Memory of...

*Christine M. Maziarz-
Ed & Jennifer Ciecko
Mr. & Mrs. Gregory Kaspiowicz
Betty Frank
Gregory Maziarz*

*Erin Dewjea-
Bill & Cecilia Sparks
Michael Farkas*

*Christine A. Madden-
Strategic Financial Services;
Alan & Connie Leist and
Alan & Nina Leist
Jay-K Independent Lumber Corp.
Mary Kazanjian
Alfred & Ruth Schulz
Joan F. Madden & Family*

*Oscar Mclain-
Ellen C. Gloom*

*Bernice Birnbaum-
Irene Fried*

Tributes

In Loving Honor of...

*Geri Lemke-
Friends & Family,
Virginia Merola*

*Monica & Rocco Falitico-
Virginia Merola*

*Patricia Mitchell's Birthday-
David & Kathleen Arntsen*

*James Mitchell's Birthday-
David & Kathleen Arntsen*

*Shane Perry-
Marion Brooks*

Memorials, Tributes, and Donations

Donations

*CFC, SEFA, United Way, IBM, GE, Amex,
United Health and Pfizer Employee Donor Plans
Pfizer, Inc.,
Pharmaceutical Research & Manufacturers
of America (PhRMA)
Carnival Cruise Foundation
PWR Strategies, Inc.
Lupus Research Institute National Coalition
GE Foundation
Astellas Pharma US
AstraZeneca
Biotechnology Industry Organization
NY State Correctional Officers & PBA—
Marcy Sector
Carbone
ΒΣφ Alpha Iota Oneonta Chapter
DTM²
James & Patricia Mitchell
Utica Professional Fire Fighters IAFF Local 32
Walmart Stores #1677 & #2285 & #6038
Family & Friends of Geri Lemke
David & Kathleen Arntsen
Buyer of Gold & Silver Coins & Jewelry
Teague Accounting Xperts
UFCW District Union Local ONE
Americu Credit Union, Commercial Drive Branch
Ellen Gloo
Presto Print, LLC
Putnam Pest Control
Raquel Rosen, MD
Scharf Plumbing & Heating
Arthritis Health Associates
Assemblyman Anthony Brindisi
Rocco & Monica Falitico in Honor of Roxanne
Rick & Kathryn Voskuil
Rick Deyulio
Gates-Cole Insurance
Edward B. Lee, MD
Tony & Anna Maria Maritato
MCORP—Dan & Lisa Mitchell
NY State Iron Workers
Pierce Auto Parts
Sea Shell Inn Waterfront Restaurant*

Donations

*Troy Waffner
Larry & Kathy Scharf
Nice N Easy Grocery Shoppes
Stampede Steakhouse & Saloon
Helen Sarandrea, Physical Therapy
Peter DeCarlo & Family
Compson & Pimipinella, PLLC
Salvatore DiStefano
Mark O'Rourke, Esq.
Harter Secrest & Emery, LLP
John Herron
Michelle Millias
Marc & Diane Chevrier
Brigiette Williams
Bob Walseman & Isabel Woolshlager*

World Lupus Day Tea

*David & Kathleen Arntsen
Rocco & Monica Falitico
Tom & Jackie Taylor
Larry & Kathy Scharf
Richard & Helen Lenart
Donald & Sharon Lust
Laurie Domanico
Jack & Marcia Flint & Family
in honor of Cathy Walseman
Bill & Sandi Frear
Robert & Jennifer Porter
James & Patricia Mitchell
Phil & Kathy Teague
Ellen Gloo
Frank & Stephanie Darwak
Dale & Maryrose Bullock
Frank, Mary & Carl Della Posta
Frances S. Eck
Cynthia Donaldson
Elisabeth Hawkins
John & Anne McQuaid
Jane Williams
Victoria Jupin
Jerry & Georgie Porter
Helen Cassin*



AWARENESS AND ADVOCACY IN ACTION

